Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

LSKL TFA

Copy Product Info
😃Good
Catalog No. TP2147Cas No. 2828433-17-4
Alias LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA), H-Leu-Ser-Lys-Leu-NH2 TFA(283609-79-0 TFA), H-Leu-Ser-Lys-Leu-NH2 TFA

LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage.

LSKL TFA

LSKL TFA

Copy Product Info
😃Good
Purity: 99.33%
Catalog No. TP2147Alias LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA), H-Leu-Ser-Lys-Leu-NH2 TFA(283609-79-0 TFA), H-Leu-Ser-Lys-Leu-NH2 TFACas No. 2828433-17-4
LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$38-In Stock
5 mg$82-In Stock
10 mg$117-In Stock
25 mg$232-In Stock
50 mg$343-In Stock
100 mg$497-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.33%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage.
In vitro
LSKL TFA from the latent form of TGF-β is responsible for the interaction with the KTFR sequence from ADAMTS1, leading to TGF-β activation. There is a stable binding mode between LSKL, Inhibitor of Thrombospondin (TSP-1) and ADAMTS1 KTFR sequence, characterized by 3 salt bridges and 2 hydrogen bonds. [3]
In vivo
Intraperitoneal injection of 1 mg/kg LSKL TFA, into male rats exerted a protective effect against subarachnoid fibrosis, attenuated ventricular enlargement, and effectively inhibited the development of hydrocephalus. [1]
Intraperitoneal injection of 30 mg/kg LSKL TFA, was able to successfully inhibit the Smad signaling pathway activated by transforming growth factor-β (TGF-β) after partial hepatectomy. LSKL effectively attenuated the activation of TGF-β-Smad signaling by antagonizing TSP-1 rather than reducing TSP-1 protein expression. [2]
SynonymsLSKL, Inhibitor of Thrombospondin (TSP-1) (TFA), H-Leu-Ser-Lys-Leu-NH2 TFA(283609-79-0 TFA), H-Leu-Ser-Lys-Leu-NH2 TFA
Chemical Properties
Molecular Weight572.62
FormulaC23H43F3N6O7
Cas No.2828433-17-4
SmilesO=C(O)C(F)(F)F.CC(C)C[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@@H](N)CC(C)C)=O)=O)=O
Relative Density.no data available
SequenceH-Leu-Ser-Lys-Leu-NH2
Sequence ShortLSKL
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 200 mg/mL (349.27 mM), Sonication is recommended.
H2O: 80 mg/mL (139.71 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (8.73 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
H2O/DMSO
1mg5mg10mg50mg
1 mM1.7464 mL8.7318 mL17.4636 mL87.3179 mL
5 mM0.3493 mL1.7464 mL3.4927 mL17.4636 mL
10 mM0.1746 mL0.8732 mL1.7464 mL8.7318 mL
20 mM0.0873 mL0.4366 mL0.8732 mL4.3659 mL
50 mM0.0349 mL0.1746 mL0.3493 mL1.7464 mL
100 mM0.0175 mL0.0873 mL0.1746 mL0.8732 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy LSKL TFA | purchase LSKL TFA | LSKL TFA cost | order LSKL TFA | LSKL TFA chemical structure | LSKL TFA in vivo | LSKL TFA in vitro | LSKL TFA formula | LSKL TFA molecular weight